Not applicableStudy completedNCT03989297What this trial is testingPD-L1 and BRAF Expression in Nasopharyngeal CarcinomaWho this might be right forNasopharyngeal Carcinoma Kiang Wu Hospital 104
Not applicableStudy completedNCT05941676What this trial is testingPrognostic Immune Biomarkers in HNSCCWho this might be right forHead and Neck CancerSquamous Cell Carcinoma University Hospital Ostrava 55
Testing effectiveness (Phase 2)Study completedNCT03727880What this trial is testingStudy of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaWho this might be right forResectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma Lei Zheng 28
Testing effectiveness (Phase 2)UnknownNCT03996408What this trial is testingStudy of TQB2450 Combined With Anlotinib in Subjects With Advanced CholangiocarcinomaWho this might be right forAdvanced Cholangiocarcinoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691What this trial is testingTobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 83
Testing effectiveness (Phase 2)Ended earlyNCT04856176What this trial is testingSargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyWho this might be right forAdvanced Lung Non-Small Cell CarcinomaNon-Small Cell Carcinoma of Lung, TNM Stage 4 Tufts Medical Center 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523What this trial is testingAZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCWho this might be right forNon-Small-Cell Lung Carcinoma AstraZeneca 212
Testing effectiveness (Phase 2)Looking for participantsNCT05492123What this trial is testingNivolumab-ipilimumab and Chemoradiation for Cervical CancerWho this might be right forUterine Cervical Neoplasms Hospital Israelita Albert Einstein 112
Early research (Phase 1)Study completedNCT03381768What this trial is testingPeptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular LymphomaWho this might be right forFollicular Lymphoma Lars Møller Pedersen 8
Testing effectiveness (Phase 2)UnknownNCT05004974What this trial is testingSintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerWho this might be right forAdvanced Non Small Cell Lung Cancer The Fourth Affiliated Hospital of Zhejiang University School of Medicine 20
Testing effectiveness (Phase 2)Study completedNCT03373760What this trial is testingDurvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerWho this might be right forRecurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7 SWOG Cancer Research Network 67
Large-scale testing (Phase 3)UnknownNCT05042375What this trial is testingA Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Jiangsu HengRui Medicine Co., Ltd. 450
Not applicableUnknownNCT05996263What this trial is testingPrognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)Who this might be right forLung Cancer Stage IIILung Cancer Stage IV University Hospital, Brest 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT06162572What this trial is testingPhase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer (NSCLC) Servier Bio-Innovation LLC 102
Large-scale testing (Phase 3)Study completedNCT04205812What this trial is testingPlatinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerWho this might be right forMetastatic Squamous Non-Small Cell Lung CancerMetastatic Nonsquamous Non-Small Cell Lung Cancer Incyte Corporation 583
Testing effectiveness (Phase 2)Ended earlyNCT03430466What this trial is testingAnti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast CancerWho this might be right forBreast Cancer Kyoto Breast Cancer Research Network 1
Large-scale testing (Phase 3)Study completedNCT02504372What this trial is testingStudy of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)Who this might be right forNon-small Cell Lung Cancer Merck Sharp & Dohme LLC 1,177
Early research (Phase 1)Ended earlyNCT03502681What this trial is testingA Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer PatientsWho this might be right forMetastatic Urothelial Cell Cancer Monika Joshi, MD 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT06727565What this trial is testingStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Who this might be right forHead and Neck Squamous Cell Carcinoma Gilead Sciences 39
Early research (Phase 1)Study completedNCT01938612What this trial is testingA Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursWho this might be right forAdvanced Solid Tumors AstraZeneca 269